You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis
|
|---|---|
| Published in |
Journal of Hematology & Oncology, June 2015
|
| DOI | 10.1186/s13045-015-0172-y |
| Pubmed ID | |
| Authors |
Xin Cao, Qing Ye, Robert Z. Orlowski, Xiaoxiao Wang, Sanam Loghavi, Meifeng Tu, Sheeba K. Thomas, Jatin Shan, Shaoying Li, Muzaffar Qazilbash, C. Cameron Yin, Donna Weber, Roberto N. Miranda, Zijun Y. Xu-Monette, L. Jeffrey Medeiros, Ken H. Young |
| Abstract |
The prognostic importance of extramedullary involvement in patients with Waldenström macroglobulinemia (WM) at diagnosis and treatment options for these patients has not been well evaluated. In this study, we investigate the clinical manifestations, biological features, and effect of first-line therapy on the outcome of WM patients diagnosed with extramedullary involvement (EMWM) vs those with only bone marrow involvement (BMWM). We analyzed the clinical data of 312 WM patients diagnosed with EMWM (n = 106) and BMWM (n = 206) at The University of Texas MD Anderson Cancer Center from 1994 to 2014. EMWM was confirmed by biopsy, positron emission tomography-computed tomography, or magnetic resonance imaging, and clinical laboratory analyses. Characteristics associated with EMWM were male sex (P = 0.027), age younger than 65 years (P = 0.048), presence of B symptoms (P < 0.001), high serum beta-2 macroglobulin (P < 0.001) level, low serum albumin level (P = 0.036), and cytogenetic abnormalities (P = 0.010). Kaplan-Meier survival analysis results showed that EMWM patients had a significantly shorter median overall survival (P < 0.001) and progression-free survival (PFS) (P < 0.001) than did BMWM patients. Chemotherapy combined with targeted therapy improved PFS for BMWM patients (P = 0.004) but not for EMWM patients. Additionally, initial treatment with rituximab significantly improved the PFS of BMWM patients (P = 0.012) but had no effect on EMWM patients. However, EMWM patients treated with nucleoside analogs attained a better PFS than those who did not (P = 0.021). We show that extramedullary involvement at diagnosis is an adverse prognostic factor in WM patients and that first-line therapy with nucleoside analogs improved PFS for patients with EMWM. The study provides unique clinical and treatment observations in subtypes of WM patients. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 43% |
| Unknown | 4 | 57% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 3 | 43% |
| Practitioners (doctors, other healthcare professionals) | 2 | 29% |
| Members of the public | 1 | 14% |
| Science communicators (journalists, bloggers, editors) | 1 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 4% |
| Unknown | 25 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 4 | 15% |
| Student > Bachelor | 3 | 12% |
| Professor | 2 | 8% |
| Student > Master | 2 | 8% |
| Student > Ph. D. Student | 2 | 8% |
| Other | 4 | 15% |
| Unknown | 9 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 50% |
| Biochemistry, Genetics and Molecular Biology | 2 | 8% |
| Psychology | 1 | 4% |
| Engineering | 1 | 4% |
| Unknown | 9 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 August 2015.
All research outputs
#12,735,689
of 22,815,414 outputs
Outputs from Journal of Hematology & Oncology
#580
of 1,191 outputs
Outputs of similar age
#113,712
of 264,049 outputs
Outputs of similar age from Journal of Hematology & Oncology
#12
of 31 outputs
Altmetric has tracked 22,815,414 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,191 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,049 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.